Clinical trials: cGVHD
Chronic Low Back Pain, Fear of Pain
The VIGOR Study - Virtual Immersive Gaming to Optimize Recovery in Low Back Pain
This study will measure the effects of interactive, whole-body video games on movement behavior in people with chronic low back pain.
- Conditions
- Chronic Low Back Pain, Fear of Pain, Fear of Injury
- Trial name
- VIGOR (NCT03463824)
- Testing
- Experimental Group 1, Experimental Group 2
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Virginia Commonwealth University
Chronic Pain
Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain
Investigators will compare Clinical Decision Support (CDS) versus Patient Education and Activation Tools (PEATs) in patients prescribed long-term or multiple opioids to measure outcomes that are important to patients.
- Trial name
- NCT03301623
- Testing
- Clinical Decision Support, Patient Education and Activation Tools
- Where
- United States
- Volunteers
- 983 people
- Sponsor
- Cedars-Sinai Medical Center
Hernia, Diaphragmatic, Hypertension, Pulmonary
Chronic Sildenafil for Severe Diaphragmatic Hernia
The purpose of this study is to test if sildenafil is effective in the treatment of infants with severe congenital diaphragmatic hernia (determined by the presence of prolonged pulmonary hypertension or prolonged oxygen…
- Conditions
- Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
- Trial name
- NCT00133679
- Testing
- sildenafil
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Acidosis
Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease and low serum bicarbonate levels.
- Trial name
- NCT02809183
- Testing
- TRC101
- Where
- 5 sites in Bulgaria, Georgia
- Volunteers
- 135 people
- Sponsor
- Tricida, Inc.
End Stage Renal Disease
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted…
- Trial name
- MiD (NCT01779856)
- Testing
- REVEAL Insertable Cardiac Monitor (ICM)
- Where
- 10 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Immune Thrombocytopenia
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
- Trial name
- NCT04638829
- Testing
- Avatrombopag Oral Tablet
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sobi, Inc.
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
Chronic Idiopathic Urticaria
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01292473
- Testing
- Omalizumab
- Where
- 61 sites in United States, Denmark and 6 more
- Volunteers
- 323 people
- Sponsor
- Genentech, Inc.
Leukemia
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
The goal of this clinical research study is to learn if combining Sprycel (dasatinib) and Dacogen (decitabine) can help to control Chronic Myeloid Leukemia (CML). The dose level of decitabine will also be studied.
- Trial name
- NCT01498445
- Testing
- Dasatinib, Decitabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Ulcer of Lower Extremity
Topical Nitric Oxide Trial in Chronic Non-Healing Wounds
To determine the effects of topically applied ViaNOx-H for 8 hours daily for 2 weeks on the reduction of the bio-burden in biofilms on chronic non-healing wounds as recorded by measurements of wound size and wound culture.
- Trial name
- NCT00823095
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Loma Linda University
Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance
Using Mirabegron to Increase BP in Patients With POTS
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and…
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
- Trial name
- RAISE-BP (NCT06133075)
- Testing
- Mirabegron 50 MG, Mirabegron 25 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Leukemia
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
The goal of this clinical research study is to find out if using the PR1 peptide vaccine (PR1) without PEG-Intron® (interferon) or in combination with interferon can reduce or eliminate disease in patients who have CML that is in…
- Trial name
- NCT00415857
- Testing
- Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
- Trial name
- NCT01090973
- Testing
- LBH589
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Stem Cell Transplantation, Ventricular Dysfunction, Left
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- TAC-HFT (NCT00768066)
- Testing
- Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Miami
Hunter Syndrome
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously.
- Trial name
- NCT00920647
- Testing
- Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Shire
Chronic Myelogenous Leukemia
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to…
- Trial name
- MACS0999 (NCT00980018)
- Testing
- Nilotinib
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Stenosis, Restenosis
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
- Trial name
- AVeVA (NCT02790606)
- Testing
- Covera(TM) Vascular Covered Stent
- Where
- 16 sites in United States
- Volunteers
- 110 people
- Sponsor
- C. R. Bard
Opioid Use, Chronic Pain
Mindfulness Oriented Recovery Enhancement for Chronic Pain and Opioid Relapse
The objective of this study is to rigorously examine the impact of online MORE, delivered through video conference, on opioid use and chronic pain among individuals receiving methadone maintenance treatment (MMT).
- Trial name
- NCT04491968
- Testing
- Mindfulness Oriented Recovery Enhancement, Methadone Treatment as Usual
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Rutgers, The State University of New Jersey
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Epilepsy
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
- Trial name
- NCT02316847
- Testing
- diazepam nasal spray
- Where
- 33 sites in United States
- Volunteers
- 126 people
- Sponsor
- Acorda Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.